Pemphigus Vulgaris – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pemphigus Vulgaris – Drugs In Development, 2024 report and make more profitable business decisions.
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender, and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, and skin blisters that come and go. The blisters always occur near the surface of the skin and there is oozing, crusting, or peeling at the blister site.
The Pemphigus Vulgaris drugs in development market research report provide comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pemphigus Vulgaris | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pemphigus Vulgaris therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pemphigus Vulgaris pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pemphigus Vulgaris treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Argenx SEBioXpress Therapeutics SA
Cabaletta Bio Inc
CSPC NBP Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
iBio Inc
ImmunoWork LLC
Octagon Therapeutics Inc
Philipps University of Marburg
SaxoCell
Serpin Pharma LLC
Topas Therapeutics GmbH
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pemphigus Vulgaris reports